Core Viewpoint - MoonLake Immunotherapeutics faces a class action lawsuit following disappointing Phase 3 trial results for its drug candidate sonelokimab, which failed to demonstrate efficacy compared to a competitor's product, leading to a significant drop in stock price [2][3]. Company Overview - MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing innovative therapies, particularly in the field of immunotherapy [1]. Legal Proceedings - A class action lawsuit has been filed against MoonLake Immunotherapeutics, with a deadline of December 15, 2025, for shareholders to file a lead plaintiff motion [1][4]. - The lawsuit alleges that the company made materially false and misleading statements regarding its drug candidate sonelokimab and failed to disclose critical information about its efficacy compared to competitors [3]. Financial Impact - Following the announcement of the Phase 3 trial results on September 28, 2025, MoonLake's stock plummeted by $55.74, or 89.9%, closing at $6.24 per share on September 29, 2025, significantly harming investors [2].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for potential securities fraud and unlawful business practices following disappointing trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by Pomerantz LLP, which is known for its expertise in corporate and securities class litigation [5]. - Investors who purchased MoonLake securities during the Class Period have until December 15, 2025, to request appointment as Lead Plaintiff [2]. Group 2: Company Performance - On September 28, 2025, MoonLake reported unsatisfactory results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest improvements compared to placebo [4]. - Following the announcement of these results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [4].

Core Points - A securities fraud class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of the Securities Exchange Act of 1934 [3][4] - The lawsuit claims that the company made misrepresentations regarding its drug candidate, sonelokimab (SLK), which was marketed as superior to competing monoclonal antibody drugs [4] Summary by Sections Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3] - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, with no fees or expenses required from shareholders [5] Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6]

Core Viewpoint - MoonLake Immunotherapeutics faced a significant decline in share price following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a securities class action lawsuit alleging misleading statements about the drug's efficacy and trial design [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy of SLK being substantially lower than that of the competitor's FDA-approved product, BIMZELX [6]. - Following the announcement on September 28, 2025, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Statements - The lawsuit claims that MoonLake made false and misleading statements regarding SLK's advantages over BIMZELX, including assertions about superior efficacy and the unique benefits of its Nanobody structure [5][6]. - Specific allegations include misleading information about the clinical benefits of SLK compared to traditional monoclonal antibodies and the expected clinical efficacy based on its structural advantages [5]. Legal Proceedings - A securities class action has been filed against MoonLake, with a focus on the company's statements about SLK's trial design and efficacy data [1][3]. - The lead plaintiff deadline for the class action is set for December 15, 2025, and the firm Hagens Berman is actively seeking investors who suffered losses to participate in the lawsuit [3][6].

Core Viewpoint - A class-action lawsuit has been filed against KBR, Inc. alleging misleading statements made by the company prior to the cancellation of a significant military contract, which adversely affected its business outlook [1][2]. Group 1: Lawsuit Details - The lawsuit targets KBR investors who acquired securities between May 6, 2025, and June 19, 2025, and seeks to represent those who suffered substantial losses [2]. - The legal action claims that KBR executives provided an overly optimistic outlook on a crucial partnership just before its collapse [2]. Group 2: Contract Cancellation Impact - The lawsuit arises from the U.S. Department of Defense's cancellation of its global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR, announced on June 20, 2025 [3]. - Following the contract termination, KBR shares dropped over 7% due to the loss of a contract valued at up to $20 billion over a potential nine-year term [3]. Group 3: Misrepresentation Allegations - On May 6, 2025, during its Q1 earnings call, KBR assured investors that the HomeSafe partnership was "strong" and projected a mid-point revenue contribution of about $400 million for 2025 [4]. - Just weeks later, on June 19, 2025, HomeSafe disclosed the termination of the contract for cause, attributed to operational issues, which KBR allegedly knew about but did not disclose to investors [5]. Group 4: Financial Revisions - After the contract termination, KBR revised its low-end 2025 revenue guidance downward by approximately $900 million (-9%) during its Q2 2025 financial results announcement on July 31, 2025 [6]. - KBR management acknowledged operational challenges during the earnings call, raising questions about whether the company intentionally misled investors regarding the contract's status [6].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses for patients and a competitive edge for sonelokimab over traditional monoclonal antibody treatments [4]. - However, the lawsuit alleges that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Viewpoint - WPP plc is facing a class action lawsuit due to allegations of providing misleading statements about its media arm's performance, leading to a significant drop in stock price after a disappointing trading update [1]. Summary by Sections Allegations - The complaint claims that WPP's management made overly positive statements while concealing adverse facts about the company's ability to handle macroeconomic challenges and competition, resulting in a loss of market share [1]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing it to macroeconomic uncertainties and weaker new business, partly due to ongoing restructuring within WPP Media (GroupM) [1]. Stock Price Impact - Following the trading update on July 9, 2025, WPP's stock price plummeted from $35.82 per share to $29.34 per share, marking an approximate decline of 18.1% in just one day [1]. Class Action Details - Shareholders who purchased WPP shares during the class period from February 27, 2025, to July 8, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2].

Accessibility StatementSkip Navigation NEW YORK, Oct. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marex Group plc (NASDAQ: MRX). Shareholders who purchased shares of MRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marex-group-plc-loss-submission-form/?id=174491&f ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Allegations - The complaint claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [1]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted and continued to harm patients [1]. - There is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may halt all new sales of these pumps [1]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 15, 2025, with no cost or obligation to participate in the case [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of KBR, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's partnership with the U.S. Department of Defense's Transportation Command [1]. Summary by Sections Allegations - The complaint alleges that KBR's management made materially false and misleading statements about the partnership with HomeSafe, despite being aware of concerns regarding HomeSafe's ability to fulfill a global household goods contract [1]. - It is claimed that KBR's statements about its business operations and future prospects lacked a reasonable basis during the class period from May 6, 2025, to June 19, 2025 [1]. Class Action Details - Shareholders who purchased KBR shares during the specified class period are encouraged to register for the class action, with a deadline set for November 18, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to false or misleading statements [3].